CD40LG and myeloid sarcoma: The treatment of MS patients with the anti‐CD40L mAb IDEC‐131 was successful in a pilot study, although the subsequent phase II trial was halted due to the occurrence of a case of severe thromboembolism in a parallel Crohn's disease trial that evaluated IDEC‐131 17.